Our Story
Our beginning...
In preclinical research, led by Søren P. Sheikh MD, PhD, HD, the promising potential of adipose-derived stem cells was demonstrated in a rat model of erectile dysfunction.
Søren then embarked on a mission to bring safe, effective and accessible stem cell treatment to patients with erectile dysfunction - a disease with a high prevalence and a high unmet need.
In 2016, the Danish Medicines Agency approved a phase I clinical trial using autologous adipose-derived stem cells to treat erectile dysfunction after prostate cancer surgery – specifically, radical prostatectomy.
The men included in the phase I clinical trial had no erectile function and did not respond to drugs like Viagra. The results were promising, with 8 out of 11 urine continent men regaining erectile function and the ability to engage in sexual intercourse 6 months after the treatment.
The autologous adipose derived stem cells used in this clinical study required liposuction and an on-site isolation of autologous adipose-derived stem cells, limiting the availability of the treatment. Søren consequently decided to develop standardised methods to isolate and culture allogeneic, ‘off-the-shelf’ stem cells, while maintaining or even enhancing their biological effects.
Since founding Blue Cell Therapeutics, Søren has gathered a team around him to make just such an ‘off-the-shelf’ allogeneic stem cell therapy product – a curative treatment for erectile dysfunction – now known as Blue Cell Therapy.
Our company has evolved to become a highly proficient unit, comprising both the management team and a skilled and dedicated group of scientists.
